Identification of exosome protein panels as predictive biomarkers for non-small cell lung cancer

• Published in: Biological procedures online 2023-11, Vol.25 (1), p.29-17, Article 29
• Main Authors: Luo, Bin, Que, Zujun, Lu, Xinyi, Qi, Dan, Qiao, Zhi, Yang, Yun, Qian, Fangfang, Jiang, Yi, Li, Yan, Ke, Ronghu, Shen, Xiaoyun, Xiao, Hua, Li, Hegen, Wu, Erxi, Tian, Jianhui
• Format: Article
• Language: English
• Subjects: Biological markers; Biomarkers; Biopsy; Cancer therapies; Clinical outcomes; Diagnosis; Electrons; Ethylenediaminetetraacetic acid; Exosomes; Extracellular vesicles; Health aspects; Lung cancer; Lung cancer, Non-small cell; Lung cancer, Small cell; Lung diseases; Medical imaging; Metastases; Metastasis; Non-small cell lung cancer (NSCLC); Non-small cell lung carcinoma; Patients; Plasma; Proteins; Proteomes; Proteomics; Rankings; Scientific equipment and supplies industry; Small cell lung carcinoma; Transmission electron microscopy; Tumors
• ISSN: 1480-9222; 1480-9222
• DOI: 10.1186/s12575-023-00223-0

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related deaths worldwide, primarily due to its propensity for metastasis. Patients diagnosed with localized primary cancer have higher survival rates than those with metastasis. Thus, it is imperative to discover biomarkers for the early detection of NSCLC and the timely prediction of tumor metastasis to improve patient outcomes. Here, we utilized an integrated approach to isolate and characterize plasma exosomes from NSCLC patients as well as healthy individuals. We then conducted proteomics analysis and parallel reaction monitoring to identify and validate the top-ranked proteins of plasma exosomes. Our study revealed that the proteome in exosomes from NSCLC patients with metastasis was distinctly different from that from healthy individuals. The former had larger diameters and lower concentrations of exosomes than the latter. Furthermore, among the 1220 identified exosomal proteins, we identified two distinct panels of biomarkers. The first panel of biomarkers (FGB, FGG, and VWF) showed potential for early NSCLC diagnosis and demonstrated a direct correlation with the survival duration of NSCLC patients. The second panel of biomarkers (CFHR5, C9, and MBL2) emerged as potential biomarkers for assessing NSCLC metastasis, of which CFHR5 alone was significantly associated with the overall survival of NSCLC patients. These findings underscore the potential of plasma exosomal biomarkers for early NSCLC diagnosis and metastasis prediction. Notably, CFHR5 stands out as a promising prognostic indicator for NSCLC patients. The clinical utility of exosomal biomarkers offers the potential to enhance the management of NSCLC.